Volume 7 Issue 1
Jun.  2023
Turn off MathJax
Article Contents
Article Navigation >  Blood&Genomics  > 2023  >  7(1): 1-12
Panpan Zhu, Yibo Wu, Yi Luo. ABO-incompatible allogeneic hematopoietic stem cell transplantation[J]. Blood&Genomics, 2023, 7(1): 1-12. doi: 10.46701/BG.2023012022036
Citation: Panpan Zhu, Yibo Wu, Yi Luo. ABO-incompatible allogeneic hematopoietic stem cell transplantation[J]. Blood&Genomics, 2023, 7(1): 1-12. doi: 10.46701/BG.2023012022036
shu

ABO-incompatible allogeneic hematopoietic stem cell transplantation

doi: 10.46701/BG.2023012022036
  • 1.

    Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 311121, China

  • 2.

    Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, Zhejiang 311121, China

  • 3.

    Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang 311121, China

  • 4.

    Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang 311121, China

More Information
  • Corresponding author: Yi Luo, Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 311121, China. E-mail: luoyijr@zju.edu.cn
  • Received Date: 2022-11-28
  • Rev Recd Date: 2023-04-17
  • Accepted Date: 2023-05-25
    • Available Online: 2023-07-05
  • Publish Date: 2023-06-30
    Abstract
  • ABO blood group incompatibility is not a contraindication for allogeneic hematopoietic stem cell transplantation (allo-HSCT). An increasing number of ABO-incompatible HSCT (ABOi-HSCT) procedures have been performed along with advances in donor selection over the years. Currently, whether the recipient-donor ABO incompatibility has detrimental effects on post-HSCT outcomes is a matter of debate. Discrepancies across studies referring to various graft sources, donor types, conditioning regimens, and the use of immunomodulators complicate interpretations of the clinical outcomes of ABOi-HSCT, such as transfusion requirements, graft-versus-host disease (GVHD), disease relapse, overall survival (OS), and non-relapse mortality (NRM). Isohemagglutinins (ISO) targeting red blood cell (RBC) antigens are associated with post-HSCT immunohematological complications, including hemolysis, passenger lymphocyte syndrome (PLS), and pure red cell aplasia (PRCA). Immunohematological events occur frequently and are sometimes difficult to handle in clinical practice. Therefore, it is necessary to form a deeper understanding on the mechanism and a comprehensive management scheme for recipients of ABOi-HSCT. In this review, we summarized literature of the impact of ABO incompatibility on post-HSCT outcomes and outlined important immune-mediated hematological events.

     

    • FullText(HTML)
  • loading
    • References(102)
  • [1]
    Park M, Seo JJ. Role of HLA in hematopoietic stem cell transplantation[J]. Bone Marrow Res, 2012, 2012: 680841. doi: 10.1155/2012/680841
    [2]
    Staley EM, Schwartz J, Pham HP. An update on ABO incompatible hematopoietic progenitor cell transplantation[J]. Transfus Apher Sci, 2016, 54(3): 337−344. doi: 10.1016/j.transci.2016.05.010
    [3]
    Misevic G. ABO blood group system[J]. Blood Genom, 2018, 2(2): 71−84. doi: 10.46701/APJBG.2018022018113
    [4]
    Ataca Atilla P, Akkus E, Atilla E, et al. Effects of ABO incompatibility in allogeneic hematopoietic stem cell transplantation[J]. Transfus Clin Biol, 2020, 27(3): 115−121. doi: 10.1016/j.tracli.2020.06.008
    [5]
    Kimura F, Kanda J, Ishiyama K, et al. ABO blood type incompatibility lost the unfavorable impact on outcome in unrelated bone marrow transplantation[J]. Bone Marrow Transplant, 2019, 54(10): 1676−1685. doi: 10.1038/s41409-019-0496-2
    [6]
    ISBT Working Parties. Red Cell Immunogenetics and Blood Group Terminology[EB/OL]. https://www.isbtweb.org/isbt-working-parties/rcibgt.html.
    [7]
    Yang X, Wang G. Advances in ABO gene expression regulation[J]. Blood Genom, 2019, 3(2): 101−107. doi: 10.46701/APJBG.2019022019125
    [8]
    Yang T, Feng Z. Overview of the diversity of erythrocyte blood group antigens[J]. Blood Genom, 2020, 4(2): 115−122. doi: 10.46701/BG.2020022020123
    [9]
    Akkök ÇA, Seghatchian J. Immunohematologic issues in ABO-incompatible allogeneic hematopoietic stem cell transplantation[J]. Transfus Apher Sci, 2018, 57(6): 812−815. doi: 10.1016/j.transci.2018.10.020
    [10]
    Wang Y, Wu DP, Liu QF, et al. Donor and recipient age, gender and ABO incompatibility regardless of donor source: validated criteria for donor selection for haematopoietic transplants[J]. Leukemia, 2018, 32(2): 492−498. doi: 10.1038/leu.2017.199
    [11]
    Migdady Y, Pang Y, Kalsi SS, et al. Post-hematopoietic stem cell transplantation immune-mediated anemia: a literature review and novel therapeutics[J]. Blood Adv, 2022, 6(8): 2707−2721. doi: 10.1182/bloodadvances.2021006279
    [12]
    Guru Murthy GS, Logan BR, Bo-Subait S, et al. Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia[J]. Am J Hematol, 2023, 98(4): 608−619. doi: 10.1002/ajh.26834
    [13]
    Holbro A, Passweg JR. Management of hemolytic anemia following allogeneic stem cell transplantation[J]. Hematology, 2015, 2015: 378−384. doi: 10.1182/asheducation-2015.1.378
    [14]
    Liu S, Yang X, Wang G. Association of the ABOblood group with certain human diseases[J]. Blood Genom, 2020, 4(2): 108−114.
    [15]
    Baine IL, Hendrickson JE, Tormey CA. Chapter 4-Common significant non-ABO antibodies and blood group antigen alloimmunization[M]//Maitta RW. Clinical Principles of Transfusion Medicine, Elsevier, 2018: 25–39.
    [16]
    Flegel WA. Pathogenesis and mechanisms of antibody-mediated hemolysis[J]. Transfusion, 2015, 55(S2): S47−S58. doi: 10.1111/trf.13147
    [17]
    Chung HJ, Lee JH, Kwon SW. Significance of donor-derived isoagglutinins in ABO-incompatible hematopoietic stem cell transplantation[J]. J Clin Lab Anal, 2008, 22(6): 383−390. doi: 10.1002/jcla.20269
    [18]
    Chen J, Liu F. Analysis of ABO chimera from peripheral red cells and reticulocytes by flow cytometry and micro gel column technique in patients post-ABO-incompatible HSCT[J]. Clin Transplant, 2018, 32(2): e13175. doi: 10.1111/ctr.13175
    [19]
    Li G, Chen F, Wang N, et al. A study of blood group conversion in patients with ABO incompatible hematopoietic stem cell transplantation-a decade survey[J]. Transfus Apher Sci, 2023, 62(2): 103576. doi: 10.1016/j.transci.2022.103576
    [20]
    David B, Bernard D, Navenot JM, et al. Flow cytometric monitoring of red blood cell chimerism after bone marrow transplantation[J]. Transfus Med, 1999, 9(3): 209−217. doi: 10.1046/j.1365-3148.1999.00201.x
    [21]
    Misaki Y, Kako S, Kawamura S, et al. Persistent expression of recipient-type ABH antigen after ABO-incompatible allogeneic hematopoietic stem cell transplantation[J]. Intern Med, 2022, 61(12): 1887−1890. doi: 10.2169/internalmedicine.8315-21
    [22]
    Mueller RJ, Stussi G, Yung GP, et al. Persistence of recipient-type endothelium after allogeneic hematopoietic stem cell transplantation[J]. Haematologica, 2011, 96(1): 119−127. doi: 10.3324/haematol.2010.030288
    [23]
    de Mattos LC. Structural diversity and biological importance of ABO, H, Lewis and secretor histo-blood group carbohydrates[J]. Rev Bras Hematol Hemoter, 2016, 38(4): 331−340. doi: 10.1016/j.bjhh.2016.07.005
    [24]
    Lemaire B, Combescure C, Chalandon Y, et al. Kinetics of disappearance and appearance of isoagglutinins A and B after ABO-incompatible hematopoietic stem cell transplantation[J]. Bone Marrow Transplant, 2022, 57(9): 1405−1410. doi: 10.1038/s41409-022-01737-z
    [25]
    Nam M, Hur M, Kim H, et al. Clinical impact of recipient-derived isoagglutinin levels in ABO-incompatible hematopoietic stem cell transplantation[J]. J Clin Med, 2023, 12(2): 458. doi: 10.3390/jcm12020458
    [26]
    Gmür JP, Burger J, Schaffner A, et al. Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation[J]. Blood, 1990, 75(1): 290−295. doi: 10.1182/blood.V75.1.290.290
    [27]
    Lee JH, Lee KH, Kim S, et al. Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation[J]. Bone Marrow Transplant, 2000, 25(2): 179−184. doi: 10.1038/sj.bmt.1702121
    [28]
    Yanagisawa R, Nakazawa H, Nishina S, et al. Investigation of risk factors associated with erythrocyte engraftment after ABO-incompatible hematopoietic stem cell transplantation[J]. Clin Transplant, 2021, 35(6): e14300. doi: 10.1111/ctr.14300
    [29]
    Griffith LM, Jr JPM, Bolan CD, et al. Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation[J]. Br J Haematol, 2005, 128(5): 668−675. doi: 10.1111/j.1365-2141.2005.05364.x
    [30]
    Adkins BD, Andrews J, Sharma D, et al. Low rates of anti-recipient isohemagglutinins in ABO incompatible hematopoietic stem cell transplants[J]. Transfus Apher Sci, 2021, 60(1): 102965. doi: 10.1016/j.transci.2020.102965
    [31]
    Igarashi A, Kakihana K, Haraguchi K, et al. Anti-host isohemagglutinin production is associated with a higher risk of acute GVHD in ABO-incompatible transplantation[J]. Bone Marrow Transplant, 2012, 47(10): 1356−1360. doi: 10.1038/bmt.2012.32
    [32]
    Solves P, Saus A, Osorio J, et al. Isohaemagglutinin production after minor ABO incompatible umbilical cord blood transplantation[J]. Transfus Med, 2017, 27(2): 147−149. doi: 10.1111/tme.12386
    [33]
    Wu Y, Ni L, Liu Y, et al. Impact of donor-to-recipient ABO mismatch on outcomes of ATG-based peripheral blood stem cell-derived myeloablative conditioning haploidentical stem cell transplantation[J]. Transplant Cell Ther, 2022, 28(6): 331.e1−331.e10. doi: 10.1016/j.jtct.2022.02.020
    [34]
    Watz E, Remberger M, Ringden O, et al. Analysis of donor and recipient ABO incompatibility and antibody-associated complications after allogeneic stem cell transplantation with reduced-intensity conditioning[J]. Biol Blood Marrow Transplant, 2014, 20(2): 264−271. doi: 10.1016/j.bbmt.2013.11.011
    [35]
    Valentini CG, Metafuni E, Gallo L, et al. ABO mismatch in allogeneic hematopoietic stem cell transplant: effect on short- and long-term outcomes[J]. Transplant Direct, 2021, 7(8): e724. doi: 10.1097/TXD.0000000000001179
    [36]
    Chen Y, Wan X, Cao Y, et al. ABO incompatibility does not affect transfusion requirements or clinical outcomes of unrelated cord blood transplantation after myeloablative conditioning for haematological malignancies[J]. Blood Transfus, 2022, 20(2): 156−167. doi: 10.2450/2021.0080-21
    [37]
    La Rocca U, Barberi W, Di Rocco A, et al. Immuno-hematological monitoring after allogeneic stem cell transplantation: a single-center, prospective study of 104 patients[J]. Blood Transfus, 2022, 20(5): 404−413. doi: 10.2450/2022.0289-21
    [38]
    Zhu P, Wu Y, Cui D, et al. Prevalence of pure red cell aplasia following major ABO-incompatible hematopoietic stem cell transplantation[J]. Front Immunol, 2022, 13: 829670. doi: 10.3389/fimmu.2022.829670
    [39]
    Aung FM, Lichtiger B, Bassett R, et al. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation[J]. Br J Haematol, 2013, 160(6): 798−805. doi: 10.1111/bjh.12210
    [40]
    Liu F, Li G, Mao X, et al. ABO chimerism determined by real-time polymerase chain reaction analysis after ABO-incompatible haematopoietic stem cell transplantation[J]. Blood Transfus, 2013, 11(1): 43−52. doi: 10.2450/2012.0013-12
    [41]
    Hefazi M, Litzow M, Hogan W, et al. ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA-matched peripheral blood hematopoietic cell transplantation after reduced-intensity conditioning[J]. Transfusion, 2016, 56(2): 518−527. doi: 10.1111/trf.13353
    [42]
    Ciftciler R, Goker H, Buyukasık Y, et al. Impact of ABO blood group incompatibility on the outcomes of allogeneic hematopoietic stem cell transplantation[J]. Transfus Apher Sci, 2020, 59(1): 102597. doi: 10.1016/j.transci.2019.06.024
    [43]
    Bazarbachi A, Boumendil A, Finel H, et al. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma–a LWP-EBMT study[J]. Br J Haematol, 2020, 188(5): 745−756. doi: 10.1111/bjh.16182
    [44]
    Ma YR, Wang WJ, Cheng YF, et al. Impact of ABO incompatibility on outcomes after haploidentical hematopoietic stem cell transplantation for severe aplastic anemia[J]. Bone Marrow Transplant, 2020, 55(6): 1068−1075. doi: 10.1038/s41409-020-0779-7
    [45]
    Canaani J, Savani BN, Labopin M, et al. ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: a report from the acute leukemia working party of the EBMT[J]. Am J Hematol, 2017, 92(8): 789−796. doi: 10.1002/ajh.24771
    [46]
    Canaani J, Savani BN, Labopin M, et al. Impact of ABO incompatibility on patients' outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia-a report from the acute leukemia working party of the EBMT[J]. Haematologica, 2017, 102(6): 1066−1074. doi: 10.3324/haematol.2016.160804
    [47]
    Seebach JD, Stussi G, Passweg JR, et al. ABO blood group barrier in allogeneic bone marrow transplantation revisited[J]. Biol Blood Marrow Transplant, 2005, 11(12): 1006−1013. doi: 10.1016/j.bbmt.2005.07.015
    [48]
    Griffith LM, VanRaden M, Barrett AJ, et al. Transfusion support for matched sibling allogeneic hematopoietic stem cell transplantation (1993–2010): factors that predict intensity and time to transfusion independence[J]. Transfusion, 2019, 59(1): 303−315. doi: 10.1111/trf.14966
    [49]
    Yuan S, Yang D, Nakamura R, et al. Red blood cell and platelet transfusion support in the first 30 and 100 days after allogeneic hematopoietic cell transplant[J]. Transfusion, 2020, 60(10): 2225−2242. doi: 10.1111/trf.15961
    [50]
    Parkhideh S, Chegeni R, Mehdizadeh M, et al. Effects of ABO incompatibility on the outcome of allogeneic hematopoietic stem cell transplantation[J]. Transfus Apher Sci, 2020, 59(2): 102696. doi: 10.1016/j.transci.2019.102696
    [51]
    Yang N, Guan L, Liu Z, et al. ABO blood type incompatibility is not a risk factor of outcomes for acute myeloid leukemia (AML) patients after unmanipulated haplo-identical peripheral blood hematopoietic stem cell transplantation[J]. Ann Transplant, 2019, 24: 350−358. doi: 10.12659/AOT.916004
    [52]
    Solves P, Carpio N, Carretero C, et al. ABO incompatibility does not influence transfusion requirements in patients undergoing single-unit umbilical cord blood transplantation[J]. Bone Marrow Transplant, 2017, 52(3): 394−399. doi: 10.1038/bmt.2016.264
    [53]
    Eiz-Vesper B, Seltsam A, Blasczyk R. ABO glycosyltransferases as potential source of minor histocompatibility antigens in allogeneic peripheral blood progenitor cell transplantation[J]. Transfusion, 2005, 45(6): 960−968. doi: 10.1111/j.1537-2995.2005.04370.x
    [54]
    Bacigalupo A, Van Lint MT, Occhini D, et al. ABO compatibility and acute graft-versus-host disease following allogeneic bone marrow transplantation[J]. Transplantation, 1988, 45(6): 1091−1094. doi: 10.1097/00007890-198806000-00018
    [55]
    Ludajic K, Balavarca Y, Bickeböller H, et al. Minor ABO-mismatches are risk factors for acute graft-versus-host disease in hematopoietic stem cell transplant patients[J]. Biol Blood Marrow Transplant, 2009, 15(11): 1400−1406. doi: 10.1016/j.bbmt.2009.07.002
    [56]
    Stussi G, Muntwyler J, Passweg JR, et al. Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation[J]. Bone Marrow Transplant, 2002, 30(2): 87−93. doi: 10.1038/sj.bmt.1703621
    [57]
    Sever T, Kirkiz S, Kaya Z, et al. Impact of peri-transplant RBC transfusion and ABO incompatibility on acute graft-versus-host disease in pediatric hematopoietic stem cell transplant patients[J]. Transfus Apher Sci, 2022, 61(3): 103352. doi: 10.1016/j.transci.2022.103352
    [58]
    Kimura F, Sato K, Kobayashi S, et al. Impact of ABO-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program[J]. Haematologica, 2008, 93(11): 1686−693. doi: 10.3324/haematol.12933
    [59]
    Rowley SD, Donato ML, Bhattacharyya P. Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation[J]. Bone Marrow Transplant, 2011, 46(9): 1167−1185. doi: 10.1038/bmt.2011.135
    [60]
    Eastlund T. The histo-blood group ABO system and tissue transplantation[J]. Transfusion, 2003, 38(10): 975−988. doi: 10.1046/j.1537-2995.1998.381098440863.x
    [61]
    Kudek MR, Shanley R, Zantek ND, et al. Impact of graft–recipient ABO compatibility on outcomes after umbilical cord blood transplant for nonmalignant disease[J]. Biol Blood Marrow Transplant, 2016, 22(11): 2019−2024. doi: 10.1016/j.bbmt.2016.07.019
    [62]
    Fatobene G, Volt F, Moreira F, et al. Optimizing selection of double cord blood units for transplantation of adult patients with malignant diseases[J]. Blood Adv, 2020, 4(24): 6327−6335. doi: 10.1182/bloodadvances.2020002258
    [63]
    Konuma T, Kato S, Ooi J, et al. Effect of ABO blood group incompatibility on the outcome of single-unit cord blood transplantation after myeloablative conditioning[J]. Biol Blood Marrow Transplant, 2014, 20(4): 577−581. doi: 10.1016/j.bbmt.2013.12.563
    [64]
    Brierley CK, Littlewood TJ, Peniket AJ, et al. Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCT[J]. Bone Marrow Transplant, 2015, 50(7): 931−938. doi: 10.1038/bmt.2015.51
    [65]
    Logan AC, Wang Z, Alimoghaddam K, et al. ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation[J]. Biol Blood Marrow Transplant, 2015, 21(4): 746−754. doi: 10.1016/j.bbmt.2014.12.036
    [66]
    El Fakih R, Kotb A, Hashmi S, et al. Outcomes of allogeneic hematopoietic cell transplant for acute myeloid leukemia in adolescent patients[J]. Bone Marrow Transplant, 2020, 55(1): 182−188. doi: 10.1038/s41409-019-0667-1
    [67]
    Hows J, Beddow K, Gordon-Smith E, et al. Donor-derived red blood cell antibodies and immune hemolysis after allogeneic bone marrow transplantation[J]. Blood, 1986, 67(1): 177−181. doi: 10.1182/blood.V67.1.177.177
    [68]
    Rowley S, Liang P, Ulz L. Transplantation of ABO-incompatible bone marrow and peripheral blood stem cell components[J]. Bone Marrow Transplant, 2000, 26(7): 749−757. doi: 10.1038/sj.bmt.1702572
    [69]
    Tomac G, Bojanic I, Mazic S, et al. Haemolysis, pure red cell aplasia and red cell antibody formation associated with major and bidirectional ABO incompatible haematopoietic stem cell transplantation[J]. Blood Transfus, 2018, 16(4): 397−404. doi: 10.2450/2017.0322-16
    [70]
    Padmanabhan A, Connelly‐Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice–evidence-based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue[J]. J Clin Apheresis, 2019, 34(3): 171−354. doi: 10.1002/jca.21705
    [71]
    Mehta P, Ramprakash S, Raghuram CP, et al. Pre-transplant donor-type red cell transfusion is a safe and effective strategy to reduce isohemagglutinin titers and prevent donor marrow infusion reactions in major ABO-mismatched transplants[J]. Ann Hematol, 2021, 100(8): 2071−2078. doi: 10.1007/s00277-021-04571-3
    [72]
    Zaimoku Y, Takami A, Sato H, et al. IgM anti-recipient ABO antibodies predict acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation[J]. Int J Hematol, 2013, 98(1): 96−101. doi: 10.1007/s12185-013-1360-6
    [73]
    Teshigawara-Tanabe H, Hagihara M, Matsumura A, et al. Passenger lymphocyte syndrome after ABO-incompatible allogeneic hematopoietic stem cell transplantation; dynamics of ABO allo-antibody and blood type conversion[J]. Hematology, 2021, 26(1): 835−839. doi: 10.1080/16078454.2021.1986654
    [74]
    Sullivan JC, Comenzo R. Peripheral agglutination and hemolytic anemia following minor ABO-mismatch hematopoietic progenitor cell transplantation[J]. Blood, 2022, 140(22): 2412. doi: 10.1182/blood.2022018097
    [75]
    Moosavi MM, Duncan A, Stowell SR, et al. Passenger lymphocyte syndrome; a review of the diagnosis, treatment, and proposed detection protocol[J]. Transfus Med Rev, 2020, 34(3): 178−187. doi: 10.1016/j.tmrv.2020.06.004
    [76]
    Xu Z, Li X, Liu K, et al. Passenger lymphocyte syndrome after minor ABO-incompatible stem cell transplantation: a case report[J]. Blood Genom, 2018, 2(3): 191−193. doi: 10.46701/APJBG.2018032018122
    [77]
    Noubouossie DF, Zaanona MIA, Costa LJ, et al. Passenger lymphocyte syndrome and autoimmune hypothyroidism following hematopoietic stem cell transplantation[J]. Case Rep Immunol, 2022, 2022: 1690489. doi: 10.1155/2022/1690489
    [78]
    Worel N, Greinix HT, Keil F, et al. Severe immune hemolysis after minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation occurs more frequently after nonmyeloablative than myeloablative conditioning[J]. Transfusion, 2002, 42(10): 1293−1301. doi: 10.1046/j.1537-2995.2002.00209.x
    [79]
    Daniel-Johnson J, Schwartz J. How do I approach ABO-incompatible hematopoietic progenitor cell transplantation?[J]. Transfusion, 2011, 51(6): 1143−1149. doi: 10.1111/j.1537-2995.2011.03069.x
    [80]
    Bolan CD, Childs RW, Procter JL, et al. Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility[J]. Br J Haematol, 2001, 112(3): 787−785. doi: 10.1046/j.1365-2141.2001.02587.x
    [81]
    Worel N, Greinix HT, Supper V, et al. Prophylactic red blood cell exchange for prevention of severe immune hemolysis in minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation after reduced-intensity conditioning[J]. Transfusion, 2007, 47(8): 1494−502. doi: 10.1111/j.1537-2995.2007.01289.x
    [82]
    Cunard R, Marquez II, Ball ED, et al. Prophylactic red blood cell exchange for ABO-mismatched hematopoietic progenitor cell transplants: prophylactic RBC exchange in HPCT[J]. Transfusion, 2014, 54(7): 1857−1863. doi: 10.1111/trf.12529
    [83]
    Lee HJ, Gulbis A, De Padua Silva L, et al. Rituximab for passenger lymphocyte syndrome associated with allogeneic SCT[J]. Bone Marrow Transplant, 2008, 42(1): 67−69. doi: 10.1038/bmt.2008.79
    [84]
    Hirokawa M, Fukuda T, Ohashi K, et al. Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors[J]. Biol Blood Marrow Transplant, 2013, 19(7): 1026−1032. doi: 10.1016/j.bbmt.2013.04.004
    [85]
    Stussi G, Halter J, Bucheli E, et al. Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins[J]. Haematologica, 2009, 94(2): 239−248. doi: 10.3324/haematol.13356
    [86]
    Sahovic EA, Flick J, Graham CD, et al. Case report: isoimmune inhibition of erythropoiesis following ABO-incompatible bone marrow transplantation[J]. Am J Med Sci, 1991, 302(6): 369−373. doi: 10.1097/00000441-199112000-00009
    [87]
    Marco-Ayala J, Gómez-Seguí I, Sanz G, et al. Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question[J]. Bone Marrow Transplant, 2021, 56(4): 769−778. doi: 10.1038/s41409-020-01124-6
    [88]
    Longval T, Galimard J, Leprêtre A, et al. Treatment for pure red cell aplasia after major ABO‐incompatible allogeneic stem cell transplantation: a multicentre study[J]. Br J Haematol, 2021, 193(4): 814−826. doi: 10.1111/bjh.17463
    [89]
    Lapierre V, Oubouzar N, Aupérin A, et al. Influence of the hematopoietic stem cell source on early immunohematologic reconstitution after allogeneic transplantation[J]. Blood, 2001, 97(9): 2580−2586. doi: 10.1182/blood.V97.9.2580
    [90]
    Wada S, Asano-Mori Y, Yamamoto H, et al. No post-transplant pure red cell aplasia development in 106 major ABO incompatible cord blood transplantation[J]. Bone Marrow Transplant, 2019, 54(5): 765−768. doi: 10.1038/s41409-018-0375-2
    [91]
    Helbig G, Stella-Holowiecka B, Wojnar J, et al. Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies[J]. Ann Hematol, 2007, 86(9): 677−683. doi: 10.1007/s00277-007-0304-8
    [92]
    Booth GS, Savani BN, Langston AA. Pure red blood cell aplasia: patient management pitfalls in major ABO-incompatible haematopoietic cell transplantation[J]. Br J Haematol, 2021, 193(4): 701−702. doi: 10.1111/bjh.17465
    [93]
    Gao Y, Gao F, Shi J, et al. Successful treatment of refractory pure red cell aplasia with eltrombopag after ABO-incompatible allogeneic hematopoietic stem cell transplantation[J]. J Zhejiang Univ Sci B, 2021, 22(8): 695−700. doi: 10.1631/jzus.B2000532
    [94]
    Arslan S, Ali H, Mei M, et al. Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib[J]. Bone Marrow Transplant, 2022, 57(5): 830−833. doi: 10.1038/s41409-022-01590-0
    [95]
    Khan F, Linden MA, Zantek ND, et al. Subcutaneous bortezomib is highly effective for pure red cell aplasia after ABO-incompatible haematopoietic stem cell transplantation: letter to the editor[J]. Transfus Med, 2014, 24(3): 187−188. doi: 10.1111/tme.12121
    [96]
    Gomez-Arteaga A, Scordo M, Tamari R, et al. Use of anti-thymocyte globulin (ATG) for the treatment of pure red cell aplasia and immune-mediated cytopenias after allogeneic hematopoietic cell transplantation: a case series[J]. Bone Marrow Transplant, 2020, 55(12): 2326−2330. doi: 10.1038/s41409-020-0939-9
    [97]
    Bathini S, Holtzman NG, Koka R, et al. Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab[J]. Am J Hematol, 2019, 94(8): E216−E219. doi: 10.1002/ajh.25515
    [98]
    Rautenberg C, Kaivers J, Germing U, et al. Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantation[J]. Bone Marrow Transplant, 2020, 55(6): 1191−1193. doi: 10.1038/s41409-019-0664-4
    [99]
    Martino R, García-Cadenas I, Esquirol A. Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation[J]. Bone Marrow Transplant, 2022, 57(2): 282−285. doi: 10.1038/s41409-021-01507-3
    [100]
    Jeyaraman P, Borah P, Rajput P, et al. Daratumumab for pure red cell aplasia post ABO incompatible allogeneic hematopoietic stem cell transplant for aplastic anemia[J]. Blood Cells Mol Dis, 2021, 88: 102464. doi: 10.1016/j.bcmd.2020.102464
    [101]
    Worel N. ABO-mismatched allogeneic hematopoietic stem cell transplantation[J]. Transfus Med Hemother, 2016, 43(1): 3−12. doi: 10.1159/000441507
    [102]
    Schrezenmeier H, Körper S, Höchsmann B, et al. Transfusion support[M/OL]//Carreras E, Dufour C, Mohty M, et al. The EBMT Handbook: hematopoietic stem cell transplantation and cellular therapies. Cham: Springer, 2019: 163–169
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (441) PDF downloads(49) Cited by()
    Proportional views
    Related

    Copyright © Blood and Genomics苏公网安备 32028102000501号苏ICP备14047883号-6

    Address：Rooms 1318-19, Hollywood Plaza, 610 Nathan Road, Mongkok, Kowloon, HongKong

    E-mail：editorial_office@apjbg.com

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return